ライフサイエンスコーパス: dizziness

1 headache, somnolence, dry mouth, nausea, and dizziness).

2 and included infections, skin disorders, and dizziness.

3 reatment because of drug-related fatigue and dizziness.

4 ache, dry mouth, constipation, insomnia, and dizziness.

5 OM that is responsible for hearing loss and dizziness.

6 ss-related handicap in patients with chronic dizziness.

7 pregabalin and lorazepam were somnolence and dizziness.

8 ildren with a history of syncope or frequent dizziness.

9 n placebo reported asthenia, somnolence, and dizziness.

10 he symptoms and disabilities associated with dizziness.

11 a headache, nausea, shortness of breath, and dizziness.

12 taxia of over 2 weeks' duration or recurrent dizziness.

13 gnostic testing in syncope, near syncope, or dizziness.

14 nt who presented with fever, sore throat and dizziness.

15 se effects after eltoprazine were nausea and dizziness.

16 ciated with higher incidences of fatigue and dizziness.

17 a for the treatment of asthma and poststroke dizziness.

18 ance recovery from problems with balance and dizziness.

19 esented with a 7-day history of numbness and dizziness.

20 1.6 [1.5-1.7]), memory loss (1.8 [1.6-2.0]), dizziness (1.7 [1.6-1.8]), and vaginal discharge (1.8 [1

21 .51), urinary dysfunction (1.96, 1.34-2.80), dizziness (1.99, 1.67-2.37), fatigue (1.56, 1.27-1.91),

22 18 [7%]), headache (16 [3%] vs 12 [5%]), and dizziness (12 [2%] vs eight [3%]).

23 %]), peripheral edema (15 [23.8%] vs 0), and dizziness (14 [22.2%] vs 0).

24 laise (88%), myalgia (57%), cough (25%), and dizziness (14%).

25 01), vomiting (11.3% vs. 7.1%, P=0.008), and dizziness (15.1% vs. 11.0%, P=0.03) than the placebo gro

26 any severe (3%), headache (4%), nausea (2%), dizziness (2%), nasopharyngitis (1%), and injection site

27 more frequently in the gabapentin group were dizziness (20 [24%] in the gabapentin group vs 4 [4.9%]

28 than with EFV/FTC/TDF (72/348 vs 48/352) and dizziness (23/348 vs 86/352), abnormal dreams (53/348 vs

29 oea (3.9%, 6.8%), headache (5.9%, 6.8%), and dizziness (3.0%, 6.2%).

30 [5%], 29 [6%], and 102 [10%], respectively), dizziness (31 [3%], 36 [7%], 99 [10%], respectively), an

31 of sleep (47 [92%] vs 39 [71%]), orthostatic dizziness (42 [78%] vs 46 [81%]), depression (43 [80%] v

32 ncope; 7.5 for local site reactions; 6.8 for dizziness; 5.0 for nausea; 4.1 for headache; 3.1 for hyp

33 261 participants (24%) reported dizziness; 56% of dizzy persons described several sensat

34 nsient xenon-related symptoms, most commonly dizziness (59%), paresthesia (34%), euphoria (30%), and

35 s 6 [2%]), rash (111 [32%] vs 40 [12%]), and dizziness (63 [18%] vs 35 [10%]) than did those in the p

36 Patients reported nausea (95%), dizziness (72%), abdominal cramps (58%), headache (52%),

37 n placebo and two on seladelpar 200 mg), and dizziness (8%; one patient on placebo and two on seladel

38 ceived ondonsetron than granisetron reported dizziness (9.6% v 5.4%, respectively; P = .011) and abno

39 most common condition is chronic subjective dizziness; a refinement of earlier concepts of psychogen

40 ernative therapies for chronic and recurrent dizziness also merit investigation.

41 edness, skin swelling, nausea, vomiting, and dizziness, among others.

42 ompared to the control group (29.6% referred dizziness and 23.9% vomiting after the first IPTp-MQ adm

43 th agents were well tolerated, although more dizziness and abnormal vision were reported with ondanse

44 le drug related AEs reported were dry mouth, dizziness and anxiety in one patient and hypotension in

45 vestibular disorders experience symptoms of dizziness and balance dysfunction, resulting in falls, a

46 Dizziness and blackouts were reported by 40.0% (318/796)

47 act of falls, and the overlap between falls, dizziness and blackouts, in a population-based sample of

48 e was marked overlap in the report of falls, dizziness and blackouts.

49 cal orthostatic symptoms such as orthostatic dizziness and blurred vision, and atypical symptoms like

50 near-vision tasks and in some cases causing dizziness and discomfort.

51 sical therapists have been shown to decrease dizziness and improve postural control.

52 Dizziness and light-headedness were more common in the l

53 ome, and dysautonomias also cause persistent dizziness and may be misdiagnosed or malingering or psyc

54 nly approved antagonist for epilepsy, induce dizziness and motor impairment.

55 with ABT-418 was relatively well tolerated; dizziness and nausea were the most frequently reported a

56 ws the often-enigmatic relationships between dizziness and psychiatric symptoms.

57 Dizziness and renal insufficiency was observed more freq

58 Dizziness and somnolence were the most frequent adverse

59 uring the study, although two reported acute dizziness and were withdrawn from the study.

60 em effects of opioids including sedation and dizziness, and 2) osteoporosis caused by chronic opioid-

61 She also reported having fatigue, dizziness, and decreased appetite.

62 rial withdrawals and adverse events of rash, dizziness, and dental discoloration were more frequent a

63 Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperid

64 suffered from abdominal pain, constipation, dizziness, and dry mouth.

65 quently reported adverse events were nausea, dizziness, and headache.

66 Fatigue, dizziness, and hypertension were more commonly reported

67 Adverse experiences included nausea, dizziness, and insomnia.

68 ide and 22% receiving placebo; constipation, dizziness, and malaise were more frequent with thalidomi

69 ents reported with lorcaserin were headache, dizziness, and nausea.

70 morbidity, including hearing loss, tinnitus, dizziness, and possibly even death from brainstem compre

71 g, tiredness, breathlessness, feeling faint, dizziness, and restless legs, especially among men [for

72 ted by side effects, particularly headaches, dizziness, and skin irritation.

73 events (including abnormal dreams, anxiety, dizziness, and somnolence) were significantly more commo

74 lozapine experienced more excess salivation, dizziness, and sweating and less dry mouth and decreased

75 Various disease entities may cause dizziness, and the reported frequency of specific diagno

76 ts were fatigue, headache, nausea, diarrhea, dizziness, and vomiting.

77 rred for at least 1 month; manifestations of dizziness; and predisposing demographic, medical, neurol

78 l group had a small increase in frequency of dizziness, anemia, and infections.

79 s of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group exper

80 Anxiety and dizziness are co-morbid symptoms in a larger percentage

81 As neck disturbances combined with dizziness are commonly encountered in the clinic, the la

82 l illnesses that masquerade as 'psychogenic' dizziness are examined.

83 The subjects rated their dizziness at each phase.

84 t, in the hemizygote group; and memory loss, dizziness, ataxia, hemiparesis, loss of consciousness an

85 Somnolence, dizziness, ataxia, peripheral edema, and infection were

86 ous symptoms like chest discomfort, fatigue, dizziness, atrial fibrillation, and hypotension.

87 e misdiagnosed or malingering or psychogenic dizziness because they often present with comorbid psych

88 eatening illnesses are rare in patients with dizziness, but many have serious functional impairment.

89 Classification of dizziness by subtype (vertigo, presyncope, disequilibriu

90 tervention, rashes, subjective complaints of dizziness by the patient, and emergence reactions to ket

91 Dizziness can be difficult to diagnose, particularly in

92 ent owing to malaise, headache, and moderate dizziness (Common Terminology Criteria for Adverse Event

93 DLTs were increased ALT/AST (n = 1), dizziness, confusion, and sensory disturbances (n = 2).

94 Side-effects include dizziness, constipation, nausea, and the potential for p

95 , psychological, and medication-related) and dizziness, coupled with the multiplicity of sensations a

96 ear of falling (FoF), and chronic subjective dizziness (CSD).

97 th a fatal outcome included fever, weakness, dizziness, diarrhea, and elevated levels of blood urea n

98 tly reported adverse events for ABT-126 were dizziness, diarrhea, and fatigue (all <8% incidence).

99 f 15 patients for each event), and headache, dizziness, diarrhoea, and vomiting were the most frequen

100 ng order of frequency): hemiparesis, vertigo/dizziness, diplopia, dysarthria, nystagmus, nausea/vomit

101 eported spontaneous and provoked symptoms of dizziness, dizziness-related quality of life, and object

102 Somnolence, dizziness, dry mouth, and weight gain occurred significa

103 Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, eupho

104 d groups compared with placebo were anxiety, dizziness, dyspnoea, increased alanine aminotransferase,

105 ics included anemia, anorexia, constipation, dizziness, elevated liver function test results, fever,

106 history of double vision, soft headaches and dizziness episodes.

107 the 1991 Gulf War, such as chronic diarrhea, dizziness, fatigue, and sexual dysfunction, are due to c

108 is a rare disorder that leads to paroxysmal dizziness, fatigue, and syncope because of a temporarily

109 g because of adverse events, most frequently dizziness, fatigue, headache, and edema.

110 main side-effects were problems of balance, dizziness, feeling faint, nausea, and/or vomiting shortl

111 roup; eight [13%] in the 16-week group), and dizziness (four [7%] in the 12-week group; nine [15%] in

112 The finding of mild postural dizziness has no proven value.

113 he most common adverse effects were fatigue, dizziness, headache, and confusion.

114 nces, breast tenderness, abdominal cramping, dizziness, headache, and mood changes.

115 with at least one associated symptom (pains, dizziness, headache, sleep disturbance, inability to rel

116 ; insomnia, constipation, dry mouth, nausea, dizziness, hot flush, headache, hyperhidrosis, and palpi

117 In patients without chronic kidney disease, dizziness, hypokalaemia, and hypotension were more frequ

118 , headache in 14 (50%), malaise in 13 (46%), dizziness in nine (32%), myalgia in four (14%), and chil

119 to use of emergency contraception; a case of dizziness in the ulipristal acetate group and a molar pr

120 ents), headache (in 80%), weakness (in 66%), dizziness (in 60%), diarrhea (in 51%), abdominal pain (i

121 ea (in seven, seven, and four patients), and dizziness (in five, nine, and four patients).

122 atients with diabetes) and falling or severe dizziness (in patients without diabetes) were most frequ

123 se (in 13 [19%] of 67 patients), followed by dizziness (in six [9%] patients).

124 diazepine-like side effects (e.g., sedation, dizziness) in ocinaplon-treated patients did not differ

125 In the primary care setting, dizziness increases in frequency as a presenting complai

126 r-function tests, fatigue, nausea, headache, dizziness, insomnia, pruritus, rash, and vomiting.

127 veloped state of the empirical literature on dizziness, investigators would benefit from use of consi

128 Vestibular rehabilitation for dizziness is a simple treatment that may be suitable for

129 Dizziness is a very common disorder and probably the eas

130 Dizziness is a very common symptom and is usually manage

131 Chronic subjective dizziness is consistent with advancing research on anxie

132 zation to the common notion of 'psychogenic' dizziness is presented.

133 Dizziness is prevalent in all adult populations, causing

134 ange (> or =30 beats/min) or severe postural dizziness is required to clinically diagnose hypovolemia

135 nce is mounting that diagnosing and treating dizziness is very important in this patient group.

136 levated supine systolic BP before breakfast, dizziness/light-headedness on standing, male sex, medica

137 participant in the placebo group (headache, dizziness, lightheadedness, and chronic abdominal pain).

138 Fifty-one cases (48%) included dizziness, lightheadedness, or a feeling of disequilibri

139 Dizziness/loss of balance was the most frequently report

140 ose-related nausea (<or=28% of patients) and dizziness (<or=18% of patients) tended to resolve with c

141 on a soldier with relapsing fever, headache, dizziness, lumbago, and shin pain.

142 ons and triggering activities, suggests that dizziness may be a geriatric syndrome, similar to deliri

143 Smaller studies noted that initial dizziness may predict PCS.

144 algia, myalgia, malaise, pruritus, headache, dizziness, metallic taste, visual disturbance, circumora

145 Dizziness might be better considered a geriatric syndrom

146 ts were also more likely to have a headache, dizziness, myalgias, abdominal pain, anorexia, leukopeni

147 s requiring treatment (n = 3), rash (n = 2), dizziness (n = 1), wheezing (n = 1), and emergence react

148 Severe AEs included vomiting (n = 32), dizziness (n = 16), headache (n = 11), and convulsions (

149 n=2 [5%]), insomnia (n=1 [2%]), tinnitus and dizziness (n=1 [2%]), and thrombocytopenia (n=1 [2%]).

150 adverse events in the rasagiline group were dizziness (n=10 [12%]), peripheral oedema (n=9 [11%]), u

151 ith common and non-specific symptoms such as dizziness, nausea and vomiting, unsteady gait, and heada

152 ted symptoms five days later) were headache, dizziness, nausea, and drowsiness.

153 erse events such as asthenia, poor appetite, dizziness, nausea, and vomiting occurred significantly m

154 s included constipation, fatigue, dry mouth, dizziness, nausea, anorexia, arrhythmia, headaches, skin

155 A case (n = 107) was defined as dizziness, nausea, or vomiting occurring in a person who

156 Dizziness, nausea, somnolence, diplopia, fatigue, and ra

157 Psychiatric causes of dizziness, neuro-otologic causes of anxiety, underrecogn

158 ectile dysfunction, urinary dysfunction, and dizziness), neuropsychiatric disturbances (memory proble

159 g headache (19 [4%] vs 11 [3%] patients) and dizziness (nine [2%] vs seven [2%] patients).

160 Dizziness, nystagmus, phosphenes, and head ringing were

161 DM/Q was well tolerated; only dizziness occurred with greater frequency than with plac

162 ea (three [4%], 9 [11%], and ten [12%]), and dizziness (one [1%], four [5%], and 11 [13%]).

163 The body's failure to do so can lead to dizziness or even fainting.

164 locomotor training had a higher frequency of dizziness or faintness during treatment (P=0.008).

165 tide and three who received placebo reported dizziness or headache.

166 Side effects from enalapril included dizziness or hypotension (22% v 3% in the placebo group;

167 sitated stopping the vehicle, 22 percent had dizziness or palpitations that did not necessitate stopp

168 rcent had a syncopal episode, 11 percent had dizziness or palpitations that necessitated stopping the

169 sore throat (OR = 4.66; 95% CI: 2.89, 7.51), dizziness (OR = 4.21; 95% CI: 2.69, 6.58), and wheezing

170 ld man was seen with progressively worsening dizziness over 10 months.

171 renz (31% [104]; p<0.0001), as were rash and dizziness (p<0.0001 for both) and increases in lipid lev

172 delirium and cognitive dysfunction, fatigue, dizziness, pain, and gastrointestinal dysfunction) after

173 al-psychiatric conditions that cause chronic dizziness, permitting greater diagnostic precision and i

174 efinement of earlier concepts of psychogenic dizziness, phobic postural vertigo, and space-motion pho

175 e risk of stroke after presumed nonstroke ED dizziness presentations is very low, supporting a nonstr

176 lish stroke risk after presumed nonstroke ED dizziness presentations.

177 serious concern in emergency department (ED) dizziness presentations.

178 physical findings are either severe postural dizziness (preventing measurement of upright vital signs

179 In the community, the prevalence of dizziness ranges from 1.8% in young adults to more than

180 e improves symptoms, postural stability, and dizziness-related handicap in patients with chronic dizz

181 ntaneous and provoked symptoms of dizziness, dizziness-related quality of life, and objective measure

182 l tolerated, but asthenia, fatigue, vertigo, dizziness, sense of imbalance, and loss of concentration

183 oembolism, fatigue, depressed consciousness, dizziness, sensory neuropathy, tremor, constipation, dys

184 The experience is one of rocking dizziness similar to when the individual was originally

185 hasia (each 9%) and tremor, speech disorder, dizziness, somnolence, and disorientation (each 4%).

186 Paroxysmal dizziness spells (PDS), a unique LGI1-IgG accompaniment

187 l manifestations, and stereotypic paroxysmal dizziness spells are common with LGI1-IgG.

188 tral valve presented with a 3-day history of dizziness, subjective fever, and chills.

189 conditions that present with non-vertiginous dizziness, subjective imbalance, and psychiatric symptom

190 Survey (NHIS), which included a Balance and Dizziness Supplement, and questions about cognitive func

191 from use of consistent criteria to describe dizziness symptoms and establish diagnoses.

192 ction in flow rates and greater increases in dizziness than the normal comparison subjects.

193 Episodes of dizziness that occurred for at least 1 month; manifestat

194 In previous studies of dizziness, the prevalence of specific causes has varied

195 n runs a spectrum, ranging from headache and dizziness to coma and death, with a mortality rate rangi

196 nd evolved from complaints of somnolence and dizziness, to more pronounced signs and symptoms of cere

197 most common drug-related adverse events were dizziness, tremor, somnolence, headache, nausea, and ras

198 adverse events in the brexanolone group were dizziness (two patients in the brexanolone group vs thre

199 senting to EDs in Nueces County, Texas, with dizziness, vertigo, or imbalance were identified, exclud

200 ade 3 or higher were neutropenia (n = 2) and dizziness/vertigo (n = 1).

201 Headache, constipation, dizziness, vomiting, and dry mouth were also more freque

202 roblems of visually induced unsteadiness and dizziness (VUD, also known as visual vertigo), fear of f

203 The adjusted relative risk for dizziness was 1.38 (CI, 1.27 to 1.49) for each additiona

204 Dizziness was more common in the pregabalin group than i

205 One serious adverse event (dizziness) was rated as possibly related to MK-869.

206 ve risks for characteristics associated with dizziness were 1.69 (95% CI, 1.24 to 2.30) for anxiety,

207 Pruritus, headache, nausea, rash, and dizziness were higher with TVR plus PEG-IFN-alpha2a-riba

208 Muscle weakness and dizziness were more common in the combined-therapy group

209 similar across groups, although diarrhea and dizziness were more frequent in the febuxostat 240 mg gr

210 Mucositis, anorexia, and dizziness were more prevalent in the rotating arm during

211 Headache, anxiety, dissociation, nausea, and dizziness were the most common (>/=20%) treatment-emerge

212 Somnolence, nausea, and dizziness were the most common side effects associated w

213 tive symptoms (nausea, throat tightness, and dizziness) were prevalent later in life.

214 , such as shortness of breath, headache, and dizziness, were reported in 48 subjects (11.1% of studie

215 Vertigo is a subtype of dizziness, which results from an imbalance within the ve

216 The most common adverse event was dizziness, which was mostly transient and of mild intens

217 rse events were injection-site reactions and dizziness, which were self-limited and without sequelae.

218 170 adult patients with chronic dizziness who were randomly assigned to vestibular rehab

219 terized by brief attacks of unsteadiness and dizziness with persistent myokymia.

220 Adverse effects included somnolence and dizziness with TCAs, SNRIs, and anticonvulsants; xerosto